ArticleGenes2026
Methylation Biomarker of Chronic Heavy Alcohol Consumption (HAC), but Not Acute HAC, Predicts All-Cause Mortality in Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Article in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDue to variability in patterns of consumption as well as well-known difficulties in obtaining valid self-report from heavy drinkers, quantifying the effects of heavy alcohol consumption on mortality is challenging. Using a DNA methylation biomarker of chronic heavy alcohol consumption (HAC) named the alcohol T-score (ATS), we previously showed that chronic HAC was a strong predictor of mortality. However, whether there is a similar effect when measures of shorter-term heavy alcohol use, i.e., recent "binge" drinking, were used to predict mortality was not examined. This is a critical issue because most biomarkers of HAC assess only short-term HAC.
methodsTherefore, we examined the prediction of all-cause mortality from a DNA methylation biomarker of smoking (cg05575921), the ATS and a short-term biomarker of recent heavy alcohol use (cg07375256) in 708 subjects from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial using Cox Proportional Hazards Regression Modeling. Models were compared using Akaike's Information Criterion.
resultsThe ATS was the best single predictor among three-variable models that included controls for sex and age. Of the possible four variable models, the model consisting of age, sex, cg05575921 methylation and ATS best predicted mortality. The addition of cg07375256 methylation did not improve model performance. In sensitivity analyses using only participants who provided alcohol SR (
conclusionsAccordingly, this study indicates a strong effect of chronic HAC, but not short-term HAC, on mortality, further highlights the limitations of self-reported alcohol use in the prediction of all-cause mortality and indicates the value of assessing HAC in addition to smoking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.